The p160 ER co-regulators predict outcome in ER negative breast cancer

Melanie Spears, Steffi Oesterreich, Ilenia Migliaccio, Carolina Guiterrez, Susan Hilsenbeck, Mary Anne Quintayo, Johanna Pedraza, Alison F. Munro, Jeremy Thomas, Gill R. Kerr, Wilma J. L. Jack, Ian Kunkler, David A. Cameron, Udi Chetty, John M. S. Bartlett

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

The SRC family of ER co-regulators are frequently overexpressed in breast cancer. Overexpression of AIB1 appears to be linked to hormone resistance in HER2 positive breast cancer. However, the role of these co-regulators in ER negative disease is poorly understood. SRC1, SRC2 and AIB1 expression was determined by immunohistochemical analysis of tissue microarrays constructed from tumours within the Edinburgh Breast Conservation Series (BCS). The BCS represents a fully documented consecutive cohort of 1,812 patients treated by breast conservation surgery in a single institution. Our results demonstrate tumours that overexpress both HER2 and AIB1 were associated with markedly reduced relapse free, distant relapse free and overall survival compared to HER2 and AIB1 only overexpressing tumours irrespective of ER status. In ER negative disease both SRC1 and AIB1 were linked to early relapse and death. The SRC family of ER co-regulators is involved in early relapse and resistance in both ER negative and ER positive breast cancer challenging the conventional concept that this effect is mediated solely via the ER.
Original languageEnglish
Pages (from-to)463-472
JournalBreast cancer research and treatment
Issue number2
Publication statusPublished - Jan 2012

Keywords / Materials (for Non-textual outputs)

  • breast cancer
  • SRC1
  • SRC2
  • AIB1


Dive into the research topics of 'The p160 ER co-regulators predict outcome in ER negative breast cancer'. Together they form a unique fingerprint.

Cite this